Evidence map›Paper›PMID 36426733›Full record

ReviewStem cells translational medicine2022

Microglia: Friends or Foes in Glaucoma? A Developmental Perspective.

Iqbal Ahmad, Murali Subramani

Open access · goldAbstract readReview
In one paragraph

Review in Stem cells translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Transcriptomic Analysis of Organotypic Porcine Retina Cultures.International journal of molecular sciences · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Role of store-operated CaFrontiers in aging neuroscience · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Iqbal AhmadDepartment of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0003-1920-9835
Murali SubramaniDepartment of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
University of Nebraska Medical Center · US

Funding

Induced pluripotent stem cell approach to optic nerve regenerationR01EY022051 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI AHMAD, IQBAL · 2013 to 2022
$3.4M
Human Disease Modeling of Glaucomatous NeuropathyR01EY029778 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI AHMAD, IQBAL · 2019 to 2022
$1.7M
NEI NIH HHS R01 EY022051NEI NIH HHS R01 EY029778
6 · The paper itself

Abstract

Glaucoma is the most prevalent form of optic neuropathy where a progressive degeneration of retinal ganglion cells (RGCs) leads to irreversible loss of vision. The mechanism underlying glaucomatous degeneration remains poorly understood. However, evidence suggests that microglia, which regulate RGC numbers and synaptic integrity during development and provide homeostatic support in adults, may contribute to the disease process. Hence, microglia represent a valid cellular target for therapeutic approaches in glaucoma. Here, we provide an overview of the role of microglia in RGC development and degeneration in the backdrop of neurogenesis and neurodegeneration in the central nervous system and discuss how pathological recapitulation of microglia-mediated developmental mechanisms may help initiate or exacerbate glaucomatous degeneration.

Indexed as

GlaucomaMicrogliaAnimalsDisease Models, AnimalHumansIntraocular PressureRetinal Ganglion Cellsdegenerationglaucomamicroglianeurogenesisretinal ganglion cell

Identifiers

PMID36426733
PMCPMC9801300
OpenAlexW4309944435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.